Cell therapies offer remarkable potential but are susceptible to contamination that can compromise safety and efficacy. Mycoplasma, a common contaminant, poses significant risks due to its ability to evade detection and disrupt cell cultures. Traditional detection methods are often slow, taking weeks to deliver results, which is impractical for urgent therapies.
- Faster Detection: Real-time PCR testing drastically reduces detection time, enabling quicker response and decision-making in cell therapy production.
- Enhanced Sensitivity: Innovative PCR kits provide high sensitivity and specificity, ensuring reliable detection of contaminants even in dense cell cultures.
- Regulatory Compliance: Sartorius' testing solutions meet stringent regulatory requirements, aligning with evolving standards to facilitate market approval.
- Improved Workflow: Case studies demonstrate significant improvements in quality control processes, reducing testing time from weeks to mere hours.
- Preventive Measures: Implementing best practices in labs, such as regular screening and equipment decontamination, minimizes the risk of contamination.
- Robust Solutions: Advanced PCR methods support the integrity and safety of cell therapies, addressing critical challenges in biomanufacturing.
Learn more in our eBook about how targeted PCR testing solutions can elevate your cell therapy safety protocols, ensuring rapid, dependable results that align with industry standards.
